From GlobeNewswire: 2025-05-13 07:30:00

BrainsWay reported record quarterly sales of $11.5 million in Q1 2025, a 27% increase from Q1 2024. Operating profit reached $0.6 million, up 519%, and Adjusted EBITDA rose to $1.3 million, an 81% increase year-over-year. The Company shipped a record number of Deep TMS Systems, indicating strong demand. Full-year 2025 financial guidance was reiterated.

The financial results show a net profit increase to $1.1 million, a significant rise from the previous year. BrainsWay continues to expand market share with growing demand for their technology in various mental health indications. The Company’s global presence is expanding to key markets like Canada, Asia, India, and Europe. A conference call will be held to discuss these results.

Adjusted EBITDA, a non-IFRS measure, is used by BrainsWay to evaluate operational performance and efficiency. It excludes certain expenses like stock-based compensation and restructuring costs. The Company’s financial statements show a strong balance sheet with cash, cash equivalents, and short-term deposits totaling $71.9 million as of March 31, 2025.

The Company’s Consolidated Statements of Financial Position and Comprehensive Profit (Loss) for the first quarter of 2025 reveal a healthy financial performance. Cash flows from operating activities increased to $5.01 million, while investing activities saw a net cash used of $1.966 million. Financing activities resulted in a net cash used of $755, with an increase in cash and cash equivalents to $71.6 million.

BrainsWay’s reconciliation of Adjusted EBITDA to net profit for the first quarter of 2025 shows Adjusted EBITDA of $1.295 million, reflecting the Company’s strong financial performance. This measure helps investors evaluate the operating performance and efficiency of BrainsWay. The Company remains focused on advancing neuroscience and transforming lives through its innovative technology.



Read more at GlobeNewswire:: BrainsWay Reports First Quarter 2025 Financial Results and